Alliar Announced 4Q16 Results

USA - English

• Brazil - Português

SÃO PAULO, March 22, 2016 /PRNewswire/ -- Centro de Imagem Diagnósticos S.A. ("Alliar" or "Company") (BM&FBOVESPA: AALR3), the country's third largest diagnostic company, announces today its results for the fourth quarter of 2016 (4Q16) and full year of 2016.

Highlights:

• Net Revenue growth of 36% in 2016;
• Adjusted pro forma EBITDA reached R$207.5 million in 2016 (22.5% margin, an 81 bps increase);
• Recurring net income of R$53.7 million in the year versus a net loss of R$19.1 million in 2015; R$39.7 million excluding minority interest;
• Recurring operating cash flow of R$150.6 million in 2016, versus R$ 112.5 million in the previous year (+ 34%), resulting in a cash conversion of 74%;
• 19.9% ROIC without goodwill, an increase of 243 bps;
• Initial public offering (IPO) at BM&F Bovespa, totaling R$ 268 million in net proceeds for the Company and reducing the Net Debt/EBITDA ratio from 2.7x in 2015 to 1.7x, in addition to providing the necessary funds for the expansion plan;
• Acquisitions of Delfin (leader in diagnostic imaging in the Northeast region of Brazil) and Multilab (one of the main clinical analysis brands of Campo Grande – MS);
• Addition of 27 PSC (3 mega, 15 standard and 9 collection points), being 9 in the quarter (mega unit CDB Ana Rosa, CDB Perdizes and Multilab units);
• 18 new MRI machines (+ 18%), with a 9% increase in the average revenue per equipment;
• 68 new clinical analysis collection rooms (+ 42%); service now available in 35% of the PSCs;
• 3.3 million patient visits, a 19% increase;
• Additional ONA-3 accreditation (ONA-3 is the sector's highest quality certification, and is the internal reference for SIGA – Alliar's internal quality program);

For Further Information: ir.alliar.com

CONTACT

INVESTOR RELATIONS TEAM

Carlos Araujo | IRO
Joaquim Silva| IR Manager
Tel.: +5511 5088-1050
E-mail: [email protected] 

SOURCE Alliar

Related Links

http://ir.alliar.com